We analyzed clinical outcomes in women enrolled in the Phare Grand Ouest (PGO) program.<h4>Methods</h4>The PGO includes carriers of the <i>BRCA1</i> and <i>BRCA2</i> pathogenic variants (PV) and women at high risk without <i>BRCA PV</i>, enrolled in eight cancer genetics units. The gene discussed is BRCA2; the disease is cancer.